Seres Therapeutics Inc (NASDAQ: MCRB) on Monday, soared 2.96% from the previous trading day, before settling in for the closing price of $0.92. Within the past 52 weeks, MCRB’s price has moved between $0.54 and $2.46.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 386.36% annually for the last half of the decade. The company achieved an average annual earnings per share of 11.26%. With a float of $120.71 million, this company’s outstanding shares have now reached $135.04 million.
In an organization with 233 employees, it is important to assess its efficiency.
Seres Therapeutics Inc (MCRB) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Seres Therapeutics Inc is 20.78%, while institutional ownership is 30.16%. The most recent insider transaction that took place on Aug 16 ’24, was worth 733. In this transaction Chief Legal Officer and EVP of this company sold 873 shares at a rate of $0.84, taking the stock ownership to the 124,173 shares. Before that another transaction happened on Aug 16 ’24, when Company’s insider sold 973 for $0.84, making the entire transaction worth $817. This insider now owns 21,013 shares in total.
Seres Therapeutics Inc (MCRB) Performance Highlights and Predictions
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.37 earnings per share (EPS) for the period topping the consensus outlook (set at -0.5) by 0.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 11.26% per share during the next fiscal year.
Seres Therapeutics Inc (NASDAQ: MCRB) Trading Performance Indicators
Seres Therapeutics Inc (MCRB) is currently performing well based on its current performance indicators. A quick ratio of 0.89 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 389.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.18, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.60 in one year’s time.
Technical Analysis of Seres Therapeutics Inc (MCRB)
Let’s dig in a bit further. During the last 5-days, its volume was 9.13 million. That was better than the volume of 4.6 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 24.51%. Additionally, its Average True Range was 0.13.
During the past 100 days, Seres Therapeutics Inc’s (MCRB) raw stochastic average was set at 39.59%, which indicates a significant increase from 35.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 122.03% in the past 14 days, which was lower than the 154.87% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0105, while its 200-day Moving Average is $0.9881. However, in the short run, Seres Therapeutics Inc’s stock first resistance to watch stands at $1.0303. Second resistance stands at $1.1146. The third major resistance level sits at $1.1591. If the price goes on to break the first support level at $0.9015, it is likely to go to the next support level at $0.8570. Assuming the price breaks the second support level, the third support level stands at $0.7727.
Seres Therapeutics Inc (NASDAQ: MCRB) Key Stats
Market capitalization of the company is 144.17 million based on 151,448K outstanding shares. Right now, sales total 126,330 K and income totals -113,720 K. The company made 0 K in profit during its latest quarter, and -40,130 K in sales during its previous quarter.
